| Title |
Mechanisms and Clinical Efficacy of Lixisenatide for the Management of Type 2 Diabetes
|
|---|---|
| Published in |
Advances in Therapy, February 2013
|
| DOI | 10.1007/s12325-013-0009-4 |
| Pubmed ID | |
| Authors |
Michael Horowitz, Christopher K. Rayner, Karen L. Jones |
| Abstract |
"Incretin-based" therapies, such as the glucagon-like peptide-1 (GLP-1) receptor agonists, represent a major advance in type 2 diabetes mellitus (T2DM) treatment. GLP-1 receptor agonists differ substantially in their duration of action, frequency of administration and clinical profile. |
X Demographics
The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Switzerland | 1 | 33% |
| United Kingdom | 1 | 33% |
| Unknown | 1 | 33% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 67% |
| Science communicators (journalists, bloggers, editors) | 1 | 33% |
Mendeley readers
The data shown below were compiled from readership statistics for 55 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | 2% |
| Brazil | 1 | 2% |
| Unknown | 53 | 96% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 12 | 22% |
| Student > Ph. D. Student | 8 | 15% |
| Student > Postgraduate | 7 | 13% |
| Student > Bachelor | 6 | 11% |
| Student > Master | 5 | 9% |
| Other | 7 | 13% |
| Unknown | 10 | 18% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 25 | 45% |
| Agricultural and Biological Sciences | 5 | 9% |
| Nursing and Health Professions | 3 | 5% |
| Environmental Science | 2 | 4% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 4% |
| Other | 9 | 16% |
| Unknown | 9 | 16% |
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 20 November 2015.
All research outputs
#13,147,386
of 22,699,621 outputs
Outputs from Advances in Therapy
#923
of 2,332 outputs
Outputs of similar age
#158,369
of 287,592 outputs
Outputs of similar age from Advances in Therapy
#7
of 18 outputs
Altmetric has tracked 22,699,621 research outputs across all sources so far. This one is in the 41st percentile – i.e., 41% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,332 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.3. This one has gotten more attention than average, scoring higher than 59% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 287,592 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 44th percentile – i.e., 44% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 18 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 61% of its contemporaries.